ILC Therapeutics is at the forefront of developing a new class of engineered drugs known as hybrid interferons, which are designed to enhance therapeutic profiles compared to traditional interferons. These hybrid interferons leverage the natural immune-modulating properties of interferons, which are crucial signaling molecules in the immune system that help combat viral infections. By combining the beneficial attributes of various interferon subtypes, ILC Therapeutics aims to create first-in-class candidates that exhibit differentiated modes of action. This innovative approach is exemplified by their lead candidate, Alfacyte™, which is being developed as a broad-spectrum antiviral treatment targeting upper respiratory tract infections, including respiratory syncytial virus (RSV).

Alfacyte™ showcases a pleiotropic mechanism of action, enhancing antiviral activity in airway epithelial cells, promoting lymphocyte responses, and modulating cytokine networks to reduce inflammation in the lungs. This multifaceted approach not only increases the therapeutic potential of Alfacyte™ but also reduces the likelihood of resistance development, a common challenge with monoclonal antibodies and other antiviral agents. ILC Therapeutics is also exploring the efficacy of Alfacyte™ against a range of viral families, positioning it as a promising candidate for addressing future pandemics and bio-terror threats. Through their pioneering work in hybrid interferons, ILC Therapeutics is advancing the field of antiviral therapeutics and aiming to improve patient outcomes in virology and dermatology.

United Kingdom

ILC Therapeutics (ILCT) is a Scottish-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs. The company is focused on modulating the Innate Immune System through the development of innovative therapies. ILC Therapeutics has raised significant funding to advance its lead interferon drug candidate and has announced its first international collaboration. The company is dedicated to revolutionizing the treatment of various diseases through its cutting-edge research and development efforts.

ILC Therapeutics

Company Details